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were included in the analysis. At 10-year followup (mean duration was 5.6 to 6.7 ± 1.8 years in DDKT and 6.2 to 7.4 ± 1.7 years in LDKT), mean times of transplantation (era of transplantation) were: 1992 ± 1.6 years and 2002 ± 1.9 years for the CSA + AZA and CSA + Introduction Azathioprine (AZA) is an anti-metabolite that has been used in transplantation, autoimmune diseases and a variety of glomerular diseases for over 30 years. The active metabolite of AZA, 6-mercaptopurine, exerts its immunosuppressive effect by incorporating into cellular DNA, thereby inhibiting purine nucleotide synthesis and the synthesis and metabolism of RNA. While AZA was used as the primary immunosuppressive agent in the early days of renal transplantation, it was downgraded as an adjunctive immunosuppressive agent with the advent of cyclosporine (CSA) in the early 1980s. Over the last decade, the use of AZA continued to fade as mycophenolate mofetil (MMF) became the preferred adjunctive immunosuppressive agent with CSA in most renal transplant centers within the USA [1] .
MMF is a potent, selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), an enzyme required for the production of guanosine from inosine monophosphate in the de novo nucleotide biosynthesis pathway [2] . The greater cytostatic effect of MMF on immune cells is based on its higher affinity for the Type II isoform of IMPDH expressed in activated T and B lymphocytes than for the Type I isoform expressed in resting lymphocytes and other cell types. Therefore, in contrast to AZA, MMF has a theoretical selective inhibitory effect on activated lymphocytes and less on other cell types, a property which renders MMF a more favorable immunosuppressive agent in terms of cytotoxic effects involving other non-immune cell types (reviewed in reference [1] ).
The advent and success of MMF in renal transplantation has sparked a great interest among general nephrologists to investigate its efficacy in the treatment of common glomerulonephritis (GN). Within a few years of its introduction to transplantation, MMF was reported to be effective in the management of various types of GN including IgA nephropathy (IgAN) [3] [4] [5] , lupus nephritis (LN) [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] , membranous GN (MGN) [3, [22] [23] [24] , membranoproliferative GN (MPGN) [3] , focal segmental glomerulosclerosis (FSGS) [3, 22, 25, 26] and even possible maintenance therapy of Anti neutrophil cytoplasmic antibodies (ANCA)-associated GN [27] .
While the use of MMF has been suggested to confer reduced acute rejection episodes and better graft survival compared with AZA as adjunctive immunosuppressive therapy to calcineurin inhibitors in renal transplantation, to our knowledge, there has been no study documenting the effect of replacing AZA with MMF as adjunctive immunosuppressive therapy on the rates of renal allograft loss due to recurrence of the primary glomerular disease [28] . A previous study from the Organ Procurement and Transplantation Network/United Network for Organ Sharing (OPTN/UNOS) database comparing discharge immunosuppressive drug regimens in primary deceased donor kidney transplants (DDKT) revealed a 10% risk reduction in overall graft loss among recipients discharged with CSA + MMF compared with those receiving CSA + AZA [29] . In the current study, we aimed to use the OPTN/UNOS database to further study the impact of the replacement of AZA for MMF as an adjunctive agent to CSA-based immunosuppressive therapy on the rates of renal allograft failure due specifically to recurrence of primary renal diagnoses. It is conceivable that any significant difference in the renal allograft failure rates between the two groups may indicate a differential efficacy of MMF compared to AZA as a primary immunosuppressive agent in the treatment of various glomerular diseases in native kidneys.
Materials and methods
All data were provided by the OPTN/UNOS database. The KaplanMeier rates of renal allograft loss due to recurrence of the primary glomerular diseases stratified by glomerular diseases including IgAN, MGN, MPGN (type not specified), LN and FSGS and maintenance immunosuppressive therapy with either CSA + AZA or CSA + MMF as reported at the time of discharge and haplotype match were obtained. Loss of allograft due to disease recurrence was based on institutional reports and may not necessarily have been confirmed by biopsy. As the long-term allograft outcomes may have been influenced by the worse quality of the deceased donor kidneys in the later MMF compared to earlier AZA era, we further evaluated similar data in living donor renal transplants performed between 
Statistical analysis
The Kaplan-Meier renal allograft failure rates due to recurrence of the primary glomerular disease were determined for each of the glomerular diseases studied. Statistically significant differences in the Kaplan-Meier renal allograft failure rates due to recurrence of different primary glomerular diseases between recipients of CSA + AZA and CSA + MMF were Chi-square analysis did not reveal any statistical significant difference for ethnic background distribution between treatment groups for either deceased or living donor kidney transplantations for any glomerular disease listed. There was no statistically significant difference in the rates of allograft loss due to disease recurrence of any glomerular disease studied in the CSA + AZA compared with CSA + MMF groups. Chi-square analysis did not reveal any significant difference between the CSA + AZA and CSA + MMF groups in terms of age, gender or ethnic background for any glomerular disease listed. 95% CI, 95% confidence interval.
defined for log-rank P-values <0.05. Differences in gender, ethnicity and age between groups for each glomerular disease were analyzed based on chi-square statistics.
Results

Background characteristics
Seven thousand eight hundred and twenty-six recipients of primary DDKT (4101 CSA + AZA and 3725 CSA + MMF) and 5498 recipients of living donor kidney transplants (LDKTs) (2269 CSA + AZA and 3229 CSA + MMF) were included in the analysis. Mean duration of follow-up, gender, age and ethnic distributions among the CSA + AZA and CSA + MMF treatment groups for the different glomerular diseases are summarized in Tables 1-3 . The mean year of transplantation (i.e. era of transplantation) for all patients receiving CSA + AZA was 1992 ± 1.6 and 2002 ± 1.9 for all patients receiving CSA + MMF. Chi-square analysis revealed no statistically significant difference in any baseline characteristics for the two treatment groups for any glomerular diseases studied.
Deceased donor kidney transplantation
Among deceased donor renal transplant recipients with one of the five glomerular diseases of interest, the highest rates of renal allograft loss due to disease recurrence by 10 years were observed for MPGN, 9.2% (CSA + AZA, n = 193) and 8.4% (CSA + MMF, n = 116), FSGS, 6.5% (CSA + AZA, n = 1313) and 6.2% (CSA + MMF, n = 1425) and MGN, 5.6% (CSA + AZA, n = 380) and 4.4% (CSA + MMF, n = 614). The lowest rates of allograft loss due to disease recurrence were observed among recipients with LN, 3.5% (CSA + AZA, n = 1324) and IgAN, 2.9% (CSA + MMF, n = 855). At 10-year follow-up, there was no statistically significant difference in the Kaplan-Meier rates of renal allograft loss due to recurrence of any of the primary glomerular diseases studied between the CSA + AZA and CSA + MMF groups (Table 4) .
Living donor kidney transplantation
During the 10-year follow-up, there was no statistically significant difference in the Kaplan-Meier rates of renal allograft loss due to the recurrence of any of the glomerular diseases studied among LDKT recipients who received either CSA + AZA or CSA + MMF immunosuppression. The rates of renal allograft loss due to disease recurrence among LDKT recipients over the 10-year follow-up were noted to be highest for MGN, 8.2% (CSA + AZA, n = 229) and 9.7% (CSA + MMF, n= 435) and FSGS, 7.4% (CSA + AZA, n = 654) and 7.6% (CSA + MMF, n = 1109). The lowest rates of allograft failure due to disease recurrence at 10-year follow-up were again observed among those with LN, 2.8% (CSA + AZA, n = 592) and 3.0% (CSA + MMF, n = 530), Table 5 . Further stratification by haplotype matches of 0, 1 and 2 revealed no statistically significant difference between either the CSA + AZA or CSA + MMF groups for any of the glomerular diseases of interest, Table 5 .
Similar to DDKT, chi-square analysis for all glomerular diseases of interest between the two immunosuppressive therapy groups in terms of age, gender and ethnic background did not reveal any statistically significant differences (Tables 1-3 ).
Discussion
The current OPTN/UNOS data indicate that the rates of both deceased donor and living donor renal allograft loss due to recurrence of common glomerular diseases including IgAN, MGN, MPGN (type not specified), LN and FSGS were consistently lowest among recipients with LN and highest among recipients with FSGS and MGN at 10-year follow-up.
Persistently low rates of allograft failure due to recurrence of LN observed for recipients of either LDKT or DDKT (2.8 and 5.3% at 10-year follow-up, respectively) is in concordance with the systemic autoimmune nature of LN where chronic suppression of the immune system would be expected to reduce disease recurrence. Different Table 5 . Kaplan-Meier rates of graft loss due to recurrence of primary kidney diseases at 10-year follow-up in LDKT immunosuppressive regimens may therefore alter outcomes with respect to disease recurrence. Current data, however, revealed no difference in allograft loss due to LN recurrence between recipients of either CSA + AZA or CSA + MMF, suggesting that either regimen is sufficiently effective in suppressing the disease at long-term follow-up. The efficacy of MMF adjunctive therapy to CSA-based immunosuppression in reducing the rates of renal allograft loss due to recurrence of all glomerular diseases studied was comparable to AZA adjunctive therapy at 10-year follow-up. The observed similar outcomes between the two groups do not rule out the possibility that one adjunctive agent may be better than the other in suppressing recurrence of glomerular disease because CSA alone may have already played a dominant role in the desired immunosuppressive effect. In addition, it could be argued that the use of either AZA or MMF belongs to different clinical eras. Deceased donor kidneys could be of better quality in the AZA era and worse quality in the MMF era where lower quality kidneys are used to accommodate the increasing mismatch in supply and demand of deceased donor kidneys. Based on the OPTN/Scientific Registry of Transplant Recipients 2003 and 2007 annual reports documenting deceased donor kidney characteristics, the mean percentage of recipients receiving expanded donor criteria over the mean year ± standard error for the CSA + AZA group was 4.5 ± 2.5% versus that of 20.6 ± 1.2% for the CSA + MMF group. Given the possibility that the quality of the transplant kidney could play a role in the rate of allograft loss due to disease recurrence independent of specific immunosuppressive therapy, comparison of allograft loss due to disease recurrence between CSA + AZA and CSA + MMF in living donor kidneys was also made. Similar to DDKT, there was no difference in outcomes between the two groups receiving living donor kidneys at 10-year follow-up. To further assure that haplotype match and its associated benefit in terms of rejection episodes do not significantly alter outcomes between the two treatment groups, a sub-analysis stratified by haplotype match also did not reveal any difference between the two treatment groups.
While current OTPN/UNOS data do not suggest any difference in the rates of allograft loss due to disease recurrence between the CSA + AZA and CSA + MMF groups, it is of interest to note a favorable trend for the latter group in recipients with the primary kidney diagnosis of IgAN. Whether longer follow-up is required for the benefit of MMF over AZA to be detectable is not known.
We acknowledge several limitations to the current study including accuracy of institutional reports, under-reporting of graft loss due to disease recurrence, accuracy of diagnosis of primary disease recurrence, unknown deceased donor organ factors, recipient factors such as acute rejection episodes, change in maintenance immunosuppression, co-morbidities, infections, malignancies, smoking or other poor lifestyle habits and unknown steroid and immunosuppressive medication dosages.
In conclusion, current OTPN/UNOS data revealed that the rates of renal allograft loss due to recurrence of glomerular diseases are relatively high for FSGS and MGN but persistently low for LN, independent of living or deceased donor renal transplants and CSA + AZA or CSA + MMF immunosuppressive therapy. In addition, although previous OTPN/UNOS data revealed better overall renal allograft survival with the CSA + MMF compared to CSA + AZA combination regimen, an analysis from the same database did not reveal superiority in the CSA + MMF group in terms of renal allograft loss due specifically to primary disease recurrence of IgAN, MGN, MPGN, LN and FSGS at long-term follow-up.
